Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - daurismo
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp80c767f44d11e1fb968f6d85169c54f0
identifier: http://ema.europa.eu/identifier
/EU/1/20/1451/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Daurismo 25 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-80c767f44d11e1fb968f6d85169c54f0
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/20/1451/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - daurismo
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Daurismo is a cancer medicine containing the active substance glasdegib. Daurismo is used with another cancer medicine, cytarabine, to treat adults newly diagnosed with a blood cancer called acute myeloid leukaemia (AML). How Daurismo works In AML, cancer cells called stem cells constantly make new leukaemic cancer cells. Daurismo works by blocking a key process in these stem cells, called the Hedgehog (Hh) pathway. This reduces their ability to make new cancer cells. By blocking the Hh pathway, Daurismo can also make cancer cells more sensitive to a cancer medicine, cytarabine, used to treat AML. Combining Daurismo with the medicine cytarabine may increase how long patients are likely to live by decreasing growth of the cancer and possibly by increasing cancer cell death. If you have any questions about how Daurismo works or why this medicine has been prescribed for you, ask your doctor.
nafcillin a medicine used to treat certain types of bacterial infections. Daurismo with food and drink Do not drink grapefruit juice or eat grapefruit while on treatment with Daurismo as it may change the amount of Daurismo in your body. Pregnancy, breast-feeding and fertility Pregnancy You must not become pregnant while taking Daurismo and you must not take it if you are pregnant. Daurismo can cause severe birth defects in babies or lead to the death of an unborn baby. Your doctor will give you more information about the effects of Daurismo on the unborn baby and will carry out a pregnancy test before you start taking the medicine. You must talk to your doctor immediately if you or your partner become pregnant or suspect you could be pregnant during treatment and for 30 days after your last dose of Daurismo. If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Contraception in women and men Women You should always use effective birth control (contraception) while taking Daurismo and for at least 30 days after the last dose of Daurismo. Talk to your doctor about birth control methods that are right for you and your partner. Men Men should always use effective contraception, including condoms (with spermicide, if available), even if you have had a vasectomy, while taking Daurismo and for at least 30 days after the last dose of Daurismo. You should not donate semen at any time while you are taking Daurismo and for at least 30 days after your last dose. Breast-feeding Do not breast-feed while taking Daurismo or during the one week after the last dose of Daurismo. It is not known if Daurismo passes into your breast milk and harms your baby. Fertility Daurismo may affect male and female fertility. Talk to your doctor about fertility preservation before taking Daurismo. Driving and using machines If you feel tired, or get muscle cramps, pain or nausea (feeling sick) while on treatment with Daurismo, take special care when driving and using machines. Daurismo contains sodium This medicine contains less than 1 mmol sodium (less than 23 mg) per tablet, that is to say Daurismo is essentially sodium -free . Daurismo contains lactose This medicine contains lactose (found in milk or dairy products). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Take Daurismo once a day at about the same time every day. Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is one tablet of 100 mg taken by mouth once a day with or without food. If you get certain side effects while you are taking Daurismo (see section 4 Possible side effects ), your doctor may lower your dose or stop treatment, either temporarily or permanently. If you vomit after taking Daurismo If you vomit after taking a dose of Daurismo, do not take an extra dose, just take your next dose at the usual time. If you take more Daurismo than you should If you accidentally take too many tablets, tell your doctor, pharmacist or nurse right away. You may require urgent medical attention. If you forget to take Daurismo If you forget to take a tablet, then take it as soon as you remember unless more than 10 hours have passed since the scheduled dose time, in which case, you should skip the dose. Do not take a double dose to make up for a forgotten dose. If you stop taking Daurismo Do not stop taking Daurismo unless your doctor tells you to. It is important to take Daurismo every day, as long as your doctor prescribes it to you. If you cannot take the medicine as your doctor has prescribed, or you feel you do not need it anymore, speak with your doctor right away. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
mouth irritation Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the blister foil or bottle after EXP . The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. Do not use this medicine if the pack is damaged or shows signs of tampering. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Provided in blisters of 10 tablets. Each pack contains 30 tablets in either 3 blisters or in one plastic bottle. Not all pack sizes may be marketed. Marketing Authorisation Holder Pfizer Europe MA EEIG Boulevard de la Plaine 1050 Bruxelles Belgium Manufacturer Pfizer Manufacturing Deutschland GmbH Betriebsst tte Freiburg Mooswaldallee 1 79090 Freiburg Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA T l/Tel: +32 (0)2 554 62 Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel. + 370 52 51 4 ,
.: +359 2 970 4Magyarorsz g Pfizer Kft. Tel.: +36-1-488-37- esk republika Pfizer, spol. s r.o. Tel.: +420 283 004 Malta Vivian Corporation Ltd. Tel. +356 21344Danmark Pfizer ApS Tlf: +45 44 20 11 Nederland Pfizer bv Tel: +31 (0)800 63 34 Deutschland Pfizer Pharma GmbH Tel: +49 (0)30 550055 51Norge Pfizer AS Tlf: +47 67 52 61 Eesti Pfizer Luxembourg SARL Eesti filiaal Tel.: +372 666 7 sterreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0
Pfizer A.E. .: +30 210 6785 Polska Pfizer Polska Sp. z o.o. Tel.:+48 22 335 61 Espa a Pfizer, S.L. Tel: +34 91 490 99 Portugal Laborat rios Pfizer, Lda. Tel: +351 21 423 5France Pfizer T l: +33 (0)1 58 07 34 Rom nia Pfizer Romania S.R.L. Tel: +40 (0) 21 207 28 Hrvatska Pfizer Croatia d.o.o. Tel: +385 1 3908 Slovenija Pfizer Luxembourg SARL Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana Tel.: + 386 (0)1 52 11 Ireland Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free) +44 (0)1304 616Slovensk republika Pfizer Luxembourg SARL, organiza n zlo ka Tel.: + 421 2 3355 5 sland Icepharma hf. S mi: +354 540 8Suomi/Finland Pfizer Oy Puh./Tel: +358 (0)9 43 00 Italia Pfizer S.r.l. Tel: +39 06 33 18 Sverige Pfizer AB Tel: +46 (0)8 550 520 K Pfizer . . (Cyprus Branch) : +357 22 817United Kingdom (Northern Ireland) Pfizer Limited Tel: +44 (0) 1304 616Latvija Pfizer Luxembourg SARL fili le Latvij Tel.: + 371 670 35 This leaflet was last revised in MM/YYYY Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-80c767f44d11e1fb968f6d85169c54f0
Resource Composition:
Generated Narrative: Composition composition-en-80c767f44d11e1fb968f6d85169c54f0
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1451/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - daurismo
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp80c767f44d11e1fb968f6d85169c54f0
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp80c767f44d11e1fb968f6d85169c54f0
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1451/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Daurismo 25 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en